<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791543</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000304</org_study_id>
    <nct_id>NCT01791543</nct_id>
  </id_info>
  <brief_title>Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia</brief_title>
  <official_title>Early Feasibility Study of Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia That Has Failed Conventional Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Stevenson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effectiveness and safety of a new device called an&#xD;
      Intramural Needle Ablation Catheter (INA catheter). The INA catheter is used for locating and&#xD;
      ablating ventricular arrhythmias that have failed standard radiofrequency ablation. This&#xD;
      approach is desirable because some people have ventricular arrhythmias that originate deep&#xD;
      within the heart muscle where it is not abolished by ablation with standard catheters.&#xD;
&#xD;
      The investigators seek to determine whether the INA catheter can potentially help people who&#xD;
      have ventricular arrhythmias that have failed standard radiofrequency ablation. The&#xD;
      investigators also want to determine if it is likely to be safe, without excessive side&#xD;
      effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">August 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of Ventricular Tachycardia (VT)</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from hospitalization for recurrent Ventricular Tachycardia during the 6 months following ablation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of all serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of serious adverse events that are potentially device related and occur within 30 days of the ablation procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of ventricular arrhythmia causing significant ventricular dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>decrease in ambient ventricular arrhythmia to &lt; 5000 ventricular beats daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success</measure>
    <time_frame>Absence of inducible clinical VT at then end of the ablation procedure.</time_frame>
    <description>Defined as termination of at least one clinical or presumptive clinical monomorphic VT by Radiofrequency ablation and/or rendering that VT no longer inducible. It is recognized that this secondary efficacy endpoint will not be assessed in all patients because VT induction will not be attempted in patients in whom, in the judgment of the investigator, attempted VT induction imposes unwarranted risk of hemodynamic deterioration. A clinical or presumptive clinical VT is one that has been documented to occur spontaneously, or is within 20 ms in cycle length of a VT that has been documented to occur spontaneously.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Intramural Needle Catheter Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intramural Needle Ablation Catheter</intervention_name>
    <arm_group_label>Intramural Needle Catheter Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Monomorphic ventricular tachycardia or incessant ventricular arrhythmia (defined as &gt;20% of&#xD;
        beats due to ventricular arrhythmia including unifocal premature ventricular contractions&#xD;
        (PVCs ), couplets, nonsustained VT) that is causing a decline in LV ejection fraction to&#xD;
        less than 50%&#xD;
&#xD;
        Arrhythmia meet the following criteria:&#xD;
&#xD;
          1. Ventricular arrhythmia is recurrent and symptomatic&#xD;
&#xD;
          2. prior antiarrhythmic drug therapy has failed due to recurrent ventricular arrythmia,&#xD;
             toxicity, or intolerance&#xD;
&#xD;
               -  Age 18 or older&#xD;
&#xD;
               -  Left ventricular (LV) ejection fraction &gt; 10% as estimated by echocardiography or&#xD;
                  contrast ventriculography within the previous 90 days&#xD;
&#xD;
               -  Failed prior VT or PVC ablation due to spontaneous recurrence of the arrhythmia&#xD;
                  or frequent PVCs.&#xD;
&#xD;
               -  Able and willing to comply with all pre-, post-, and follow-up testing and&#xD;
                  requirements&#xD;
&#xD;
               -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with idiopathic VT defined as VT that originates from a region without&#xD;
             evidence of scar detected by MRI or voltage mapping in a patient without other&#xD;
             evidence of heart disease that is not causing significant depression of ventricular&#xD;
             function.&#xD;
&#xD;
          -  Definite protruding left ventricular thrombus on pre-ablation echocardiography when LV&#xD;
             ablation is required.&#xD;
&#xD;
          -  Thrombotic myocardial infarction within the preceding two (2) months.&#xD;
&#xD;
          -  Other disease process that is likely to limit survival to less than 12 months.&#xD;
&#xD;
          -  Class IV heart failure, unless heart failure is due to frequent or incessant VT.&#xD;
&#xD;
          -  Contraindication to heparin.&#xD;
&#xD;
          -  Allergy to radiographic contrast dye.&#xD;
&#xD;
          -  Severe aortic stenosis&#xD;
&#xD;
          -  Severe mitral regurgitation with a flail mitral valve leaflet.&#xD;
&#xD;
          -  Significant congenital anomaly or medical problem that in the opinion of the principal&#xD;
             investigator would preclude enrollment into the study.&#xD;
&#xD;
          -  Enrolled in another investigational study evaluating a drug or device.&#xD;
&#xD;
          -  Unstable angina that is not due to frequent or incessant VT.&#xD;
&#xD;
          -  Women who are pregnant.&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt; 50,000) or coagulopathy.&#xD;
&#xD;
          -  Acute non-cardiovascular illness or systemic infection.&#xD;
&#xD;
          -  Cardiogenic shock unless it is due to incessant VT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G. Stevenson, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt Heart and Vascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Usha Tedrow, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Heart and Vascular Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sapp JL, Cooper JM, Zei P, Stevenson WG. Large radiofrequency ablation lesions can be created with a retractable infusion-needle catheter. J Cardiovasc Electrophysiol. 2006 Jun;17(6):657-61.</citation>
    <PMID>16836718</PMID>
  </reference>
  <reference>
    <citation>Sapp JL, Beeckler C, Pike R, Parkash R, Gray CJ, Zeppenfeld K, Kuriachan V, Stevenson WG. Initial human feasibility of infusion needle catheter ablation for refractory ventricular tachycardia. Circulation. 2013 Nov 19;128(21):2289-95. doi: 10.1161/CIRCULATIONAHA.113.003423. Epub 2013 Sep 13.</citation>
    <PMID>24036605</PMID>
  </reference>
  <reference>
    <citation>Schaeffer B, Tanigawa S, Nakamura T, Muthalaly RG, Sapp J, John R, Ghidoli D, Pellegrini C, Tedrow U, Stevenson WG. Characteristics of myocardial tissue staining and lesion creation with an infusion-needle ablation catheter for the treatment of ventricular tachycardia in humans. Heart Rhythm. 2020 Mar;17(3):398-405. doi: 10.1016/j.hrthm.2019.10.007. Epub 2019 Oct 8.</citation>
    <PMID>31604127</PMID>
  </reference>
  <results_reference>
    <citation>Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, Fujii A, Schaeffer B, Tanigawa S, Elsokkari I, Koruth J, Nakamura T, Naniwadekar A, Ghidoli D, Pellegrini C, Sapp JL. Infusion Needle Radiofrequency Ablation for Treatment of Refractory Ventricular Arrhythmias. J Am Coll Cardiol. 2019 Apr 2;73(12):1413-1425. doi: 10.1016/j.jacc.2018.12.070.</citation>
    <PMID>30922472</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>William Stevenson</investigator_full_name>
    <investigator_title>Professor, Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>ventricular tachycardia</keyword>
  <keyword>ablation</keyword>
  <keyword>ventricular arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

